文献速递心力衰竭与心肌病心律失常

非缺血性心肌病、心脏性猝死与植入式除颤器:综述与荟萃分析

Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
PubMed 文献 · Heart · 2017-10-06

该综述与荟萃分析系统检索评估ICD对非缺血性心肌病(NICM)患者预后影响的研究,比较随机接受ICD与未接受ICD者的全因死亡率。共纳入6项一级预防试验和2项二级预防试验,固定效应模型分析显示一级预防试验中ICD治疗降低全因死亡率(RR 0.76,95%CI 0.65-0.91)。但作者指出该获益因纳入最大且最新的DANISH试验而实质性减弱,需谨慎解读,NICM一级预防ICD无「一刀切」适应证,应个体化考虑年龄与合并症。

要点

  • 一级预防试验荟萃显示ICD降低NICM患者全因死亡率(RR 0.76,95%CI 0.65-0.91)。
  • DANISH试验未显示ICD降低NICM总体死亡率,削弱了汇总获益。
  • NICM一级预防ICD无统一适应证,需按年龄和合并症个体化决策。

核心结论

  • 更新荟萃分析显示ICD治疗在NICM患者中仍有生存获益,但该效应因纳入DANISH试验而实质性减弱。
  • 残余的汇总获益可能反映的是较早试验中按当代标准治疗不充分患者的猝死风险,数据须谨慎解读。
  • NICM患者一级预防ICD不存在「一刀切」适应证,临床医生须基于年龄和合并症个体化判断。

研究设计与样本

  • 系统检索评估ICD对NICM患者预后影响的研究,比较随机接受ICD与未接受ICD者的全因死亡率终点。
  • 共识别6项一级预防试验和2项二级预防试验符合预设检索标准。
  • 采用固定效应模型进行分析。

主要发现

  • 一级预防试验分析显示ICD治疗降低全因死亡率(RR 0.76,95%CI 0.65至0.91)。
  • DANISH试验为所分析试验中最大且最新的一项,其纳入实质性削弱了汇总生存获益。

关键数值与推荐

  • 一级预防试验中ICD对比无ICD的全因死亡率RR 0.76(95%CI 0.65至0.91)。

临床怎么用

  • NICM患者考虑一级预防ICD时应个体化评估年龄与合并症,而非按统一标准植入。
  • 解读ICD生存获益证据时需考虑当代优化药物治疗背景及DANISH试验结果。

局限性

  • 汇总获益受DANISH试验纳入影响而实质性减弱,残余获益可能反映较早试验中治疗不充分患者的猝死风险。
  • 作者强调数据须谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) trial suggested that implantable cardioverter defibrillators (ICDs) do not reduce overall mortality in patients with non-ischaemic cardiomyopathy (NICM), despite reducing sudden cardiac death. We performed an updated meta-analysis to examine the impact of ICD therapy on mortality in NICM patients. METHODS: A systematic search for studies that examined the effect of ICDs on outcomes in NICM was performed. Our analysis compared patients randomised to an ICD with those randomised to no ICD, and examined the endpoint of overall mortality. RESULTS: Six primary prevention trials and two secondary prevention trials were identified that met the pre-specified search criteria. Using a fixed-effects model, analysis of primary prevention trials revealed a reduction in overall mortality with ICD therapy (RR 0.76, 95% CI 0.65 to 0.91). CONCLUSIONS: Although our updated meta-analysis demonstrates a survival benefit of ICD therapy, the effect is substantively weakened by the inclusion of the DANISH trial-which is both the largest and most recent of the analysed trials-indicating that the residual pooled benefit of ICDs may reflect the risk of sudden death in older trials which included patients treated sub-optimally by contemporary standards. As such, these data must be interpreted cautiously. The results of the DANISH trial emphasise that there is no 'one size fits all' indication for primary prevention ICDs in NICM patients, and clinicians must consider age and comorbidity on an individual basis when determining whether a defibrillator is appropriate.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Beggs SAS, Jhund PS, Jackson CE, et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2017. PMID: 28986406. doi:10.1136/heartjnl-2016-310850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。